Changes in HbA1c With Glucagon-Like Peptide-1 Receptor Agonist Therapy Alone and Followed by Initiation of Continuous Glucose Monitoring: A Retrospective Analysis of U.S. Medical Claims Data
Authors' conclusion
Adding CGM to GLP-1 RA therapy accelerates and enhances glycemic improvement compared with GLP-1 RA alone, regardless of prior GLP-1 RA duration. These findings support combined use to optimize T2D management and reduce time with poor glycemic control.
Study context
- Population
- Patients with T2D in IQVIA's US medical and pharmacy claims data, January 2019–December 2023matched sample
- Participants
- 13,221 patients
- Exposure
- GLP-1 RA followed by CGM initiation vs GLP-1 RA alone
- Outcome
- Change in HbA1c, assessed quarterly
- Follow-up
- 12 months
Methodological detailspropensity-score matched, US medical and pharmacy claims data
- Propensity-score matched
- US medical and pharmacy claims data
Main finding
As reported in the abstract
HbA1c >9%
Observational data: associations, not effects.
Further findings
HbA1c <7% · 12 months
Subgroups by duration of GLP-1 RA exposure before CGM initiation
- Greater odds for HbA1c reduction with CGM use held true across subgroups
Original publication
Changes in HbA1c With Glucagon-Like Peptide-1 Receptor Agonist Therapy Alone and Followed by Initiation of Continuous Glucose Monitoring: A Retrospective Analysis of U.S. Medical Claims Data. J Diabetes Sci Technol. Published 14 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →